PubRank

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Clinical Trial ID NCT00574132

PubWeight™ 42.56‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00574132

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012 14.14
2 Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014 6.50
3 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
4 Antibodies to watch in 2010. MAbs 2010 1.90
5 A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 2014 1.83
6 Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 2009 1.79
7 Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 2015 1.73
8 New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012 1.62
9 Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther 2010 1.39
10 Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012 1.31
11 Natural products as a source of Alzheimer's drug leads. Nat Prod Rep 2010 1.13
12 Bapineuzumab. Expert Opin Biol Ther 2010 1.12
13 Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 2011 1.00
14 Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009 0.97
15 Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int J Alzheimers Dis 2012 0.93
16 Novel therapeutics for Alzheimer's disease: an update. Curr Opin Drug Discov Devel 2010 0.84
17 Frontiers in Alzheimer's disease therapeutics. Ther Adv Chronic Dis 2011 0.84
18 Bapineuzumab, an investigational agent for Alzheimer's disease. P T 2013 0.80
19 Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimers Res Ther 2016 0.80
20 The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis 2014 0.78
21 Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies. PLoS One 2013 0.78
Next 100